Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Public ClinicalTrials.gov record NCT02208037. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN #1203; Progress I)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Acute Graft-versus-Host-Disease (GVHD) is an important cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). This study aims to determine if any of three new GVHD prophylaxis approaches improves the rate of GVHD and relapse free survival at one year after transplant compared to the current standard prophylaxis regimen.
Study identification
- NCT ID
- NCT02208037
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 279 participants
Conditions and interventions
Conditions
Interventions
- Tacrolimus (ARM with Methotrexate) Drug
- Tacrolimus (ARM with MMF and Cyclophosphamide) Drug
- Methotrexate (ARM with Maraviroc) Drug
- Methotrexate (ARM with Bortezomib) Drug
- Maraviroc Drug
- Bortezomib Drug
- Mycophenolate mofetil Drug
- Cyclophosphamide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2014 (Type not available)
- Primary completion
- Oct 2017 (Actual)
- Completion
- Oct 2017 (Actual)
- Last update posted
- Jan 23, 2019
2014 – 2017
United States locations
- U.S. sites
- 30
- U.S. states
- 21
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| Stanford Hospital and Clinics | Stanford | California | 94305 | — |
| University of Florida College of Medicine (Shands) | Gainesville | Florida | 32611 | — |
| H. Lee Moffitt Cancer Center | Tampa | Florida | 33624 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| BMT Program at Northside Hospital | Atlanta | Georgia | 30342 | — |
| Loyola University Medical Center | Maywood | Illinois | 60153 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| University of Kansas Hospital | Westwood | Kansas | 66205 | — |
| Johns Hopkins University | Baltimore | Maryland | 22218 | — |
| Dana Farber Cancer Institute/Massachusetts General Hospital Dana-Farber Cancer Institute | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Institute/Brigham & Women's Brigham and Women's Hospital | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute/BMT | Detroit | Michigan | 48201 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | — |
| Washington University/Barnes Jewish Hospital | St Louis | Missouri | 63130 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Memorial Sloan-Kettering Cancer Center | Manhattan | New York | 10065 | — |
| University of North Carolina Hospital at Chapel Hill | Chapel Hill | North Carolina | 27514 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44106 | — |
| University Hospitals of Cleveland/Case Western | Cleveland | Ohio | 44106 | — |
| Ohio State/Arthur G. James Cancer Hospital | Columbus | Ohio | 43210 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| University of Pennsylvania Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | — |
| University of Texas/MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Texas Transplant Institute | San Antonio | Texas | 78229 | — |
| University of Utah Med School | Salt Lake City | Utah | 84112 | — |
| Virginia Commonwealth University MCV Hospitals | Richmond | Virginia | 23284 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02208037, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 23, 2019 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02208037 live on ClinicalTrials.gov.